Coupa Software Inc., (NASDAQ: COUP) Monday said its third-quarter revenues increased in double digits, aided by solid billing growth. As a result, earnings more than doubled and topped the Street view. The company also provided guidance for the fourth quarter and fiscal 2019.
During the three-month period, there was a 51% increase in revenues to $101.8 million, which also surpassed the estimates. At $105.4 million, calculated billings were up 54% year-over-year. Subscription revenue grew 49% year-over-year to $90.2 million, while professional services and other revenue nearly doubled to $11.6 million.
On an adjusted basis, excluding special items, Coupa reported earnings of $0.20 per share, up 150% from last year and above Wall Street’s projection. On an unadjusted basis, it was a net loss of $26.3 million or $0.42 per share, compared to a loss of $9.6 million or $0.17 per share last year.
Rob Bernshteyn, Chairman and Chief Executive Officer said, “We delivered strong business and financial results for the third quarter, as we continue executing on our vision and extending our leadership position in Business Spend Management (BSM). We reported $102 million of total revenues, up 51% year-over-year, and were profitable on a non-GAAP basis for the sixth consecutive quarter.”
What to Look for
For the fourth quarter of 2020, the management expects revenues to be between $101.5 million and $102.5 million and adjusted earnings in the range of $0.03 per share to $0.06 per share. Subscription revenue is expected to be $9.5 – $9.25million and professional services revenue is estimated to be about $10 million.
For the whole of 2020, the company forecasts revenues in the range of $379.8 million to $380.8 million and adjusted earnings between $0.34 per share and $0.37 per share.
Last month, Coupa shares climbed to an all-time high after gaining steadily for more than a year. Though the stock lost momentum since then, it regained strength in recent weeks and is hovering near the peak once again.
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated
The healthcare sector is going through a phase of consolidation, creating fresh opportunities for emerging companies in a market that is slowly recovering from the pandemic. Several pharmaceuticals firms have
Shares of American Airlines Group (NASDAQ: AAL) have gained 42% since the beginning of this year and 50% over the past 12 months. Despite this, there is a mixed sentiment